{"id":4584,"date":"2016-02-11T12:06:00","date_gmt":"2016-02-11T12:06:00","guid":{"rendered":"http:\/\/congressmed.com\/cobrca\/?page_id=4584"},"modified":"2024-09-09T17:46:12","modified_gmt":"2024-09-09T17:46:12","slug":"scientific-program","status":"publish","type":"page","link":"https:\/\/cobrca.org\/cobrca2024\/scientific-program\/","title":{"rendered":"Scientific Program"},"content":{"rendered":"

Scientific Program<\/strong><\/span><\/h3>\n

Click on the picture below to view the full scientific program and abstracts <\/em>(pdf version which can be printed)\u00a0<\/em><\/p>\n

\"\"<\/a>
\nWednesday, September 11, 2024<\/strong><\/span><\/p>\n\n\n\n\n
12:00-13:00<\/strong><\/td>\nIndustry Lunch Symposium<\/span><\/strong><\/a>
\nClick HERE<\/strong><\/a> for more information<\/em>
\n<\/span><\/td>\n		Hall A<\/strong><\/span><\/td>\n<\/tr>\n
<\/td>\nLight refreshments will be served, from 07:00-07:30, to session participants only.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n
11:30-13:00<\/strong><\/td>\n<\/a>Lunch Symposium:
\nAI in breast imaging
\n<\/span><\/strong><\/span>Light refreshments will be served, from 07:00-07:30, to session participants only.<\/em><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
Chairperson<\/strong><\/td>\nYazan Masannat,<\/strong>\u00a0Essex, UK <\/em><\/td>\n<\/tr>\n
11:30-11:45<\/strong><\/td>\nHype or hope: Breast imaging and Artificial Intelligence
\nGerald Lip, <\/strong>Aberdeen, Scotland, UK<\/em><\/td>\n<\/tr>\n
11:45-12:00<\/strong><\/td>\nOptimizing breast MRI utility with AI\u00a0
\nKarla Sepulveda,<\/strong><\/strong> Houston, TX, USA<\/em>
\n<\/strong><\/strong><\/td>\n<\/tr>\n
12:00-13:00<\/strong><\/td>\nRound Table Discussion:
\n<\/strong><\/strong>James Blackwood,<\/strong> Glenboig, Scotland, UK<\/em>
\nJulia Camps Herrero,<\/strong> Valencia, Spain<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n
13:00-13:15<\/strong><\/td>\n<\/a>Congress Opening<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nLeena Chagla,<\/strong> Cheshire, UK
\n<\/em>Bruce Mann,<\/strong> Melbourne, Australia<\/em><\/td>\n<\/tr>\n
<\/td>\nWelcome from Congress chairpersons<\/strong>
\n<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n
13:15-14:40<\/strong><\/td>\n<\/a>Session 1: Neoadjuvant therapy<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nLeena Chagla,<\/strong> Cheshire, UK
\n<\/em>Bruce Mann,<\/strong> Melbourne, Australia<\/em><\/td>\n<\/tr>\n
13:15-13:50
\n<\/strong>13:15
\n13:25
\n13:35<\/td>\n		Debate: <\/strong>That cT1cN0 HER2+ve should have NAST
\n<\/strong>Yes: Javier Cortes,<\/strong> Madrid, Spain<\/em>
\n<\/strong>No: Sarah Downey, <\/strong>Norfolk, UK<\/em>\u00a0
\n<\/strong>Discussion<\/td>\n<\/tr>\n
13:50-14:05<\/strong><\/td>\nImaging during NAST
\nJulia Camps Herrero, <\/strong>Valencia, Spain<\/em><\/td>\n<\/tr>\n
14:05-14:40
\n14:05
\n14:15
\n14:25<\/strong><\/td>\n		Debate: <\/strong>Patients with a positive TAD post NACT should have completion axillary clearance\u00a0\u00a0
\n<\/strong>Yes: Stephen Grobmyer,<\/strong> Abu Dhabi, UAE<\/em>
\n<\/strong>No: Amit Goyal, <\/strong>Derby, UK <\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
14:40-15:10<\/em><\/span><\/strong><\/td>\nCoffee break, poster viewing and exhibition visit<\/em><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
15:10-16:10<\/strong><\/td>\n<\/a>Session 2: Imaging<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nNisha Sharma,<\/strong>\u00a0Leeds, UK<\/em>
\n<\/em>Karla Sepulveda,<\/strong>\u00a0Houston, TX, USA<\/em><\/td>\n<\/tr>\n
15:10-15:40
\n<\/strong>15:10
\n15:20
\n15:30<\/td>\n		Debate: <\/strong>The Contrast Breast Imaging should be routine prior to surgery for DCIS or invasive cancer\u00a0
\n<\/strong>Yes: Bruce Mann,<\/strong> Melbourne, Australia<\/em>
\n<\/strong>No: Stuart McIntosh,<\/strong>\u00a0Belfast, UK<\/em>\u00a0
\n<\/strong>Discussion<\/td>\n<\/tr>\n
15:40-16:10
\n<\/strong>15:40
\n15:50
\n16:00<\/td>\n		Debate: <\/strong>The CEM should be the surveillance imaging test for most patients with past history of breast cancer\u00a0
\n<\/strong>Yes: Allison Rose,<\/strong> Melbourne, Australia<\/em>
\n<\/strong>No: Sarah Savaridas,<\/strong> Dundee, Scotland, UK<\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n
15:10-16:10<\/strong><\/td>\n<\/a>Session 3: HER2+ve disease<\/span><\/strong><\/span><\/td>\nHall B<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nRichard de Boer,<\/strong> Melbourne, Australia
\n<\/em>Olga Oikonomidou, <\/strong>Edinburgh, Scotland, UK<\/em><\/td>\n<\/tr>\n
15:10-15:40
\n<\/strong>15:10
\n15:20
\n15:30<\/td>\n		Debate: <\/strong>Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
\n<\/strong>Yes: Richard Simcock, <\/strong>Surrey, UK <\/em>
\n<\/strong>No: Kevin Kalinsky,<\/strong> Atlanta, GA, USA<\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n
15:40-15:55<\/strong><\/td>\nHER2 low
\nSarah Pinder, <\/strong>London, UK <\/em><\/td>\n<\/tr>\n
15:55-16:10<\/strong><\/td>\nIs there a threshold for systemic treatment of HER2+ve cancer?
\nIain MacPherson, <\/strong>Glasgow, S<\/em>cotland, UK <\/em>
\n<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
16:10-17:10<\/strong><\/td>\n<\/a>Session 4: DCIS<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nBruce Mann, <\/strong>Melbourne, Australia<\/em>
\nTracey Irvine, <\/strong>Surrey, UK\u00a0<\/em><\/td>\n<\/tr>\n
16:10-16:40
\n<\/strong>16:10
\n16:20
\n16:30<\/td>\n		Debate: <\/strong>That most patients with DCIS should have radiotherapy after Breast Conserving Surgery
\nYes: Frank A. Vicini,<\/strong> Farmington Hills, MI, USA <\/em>
\nNo: Elinor Sawyer,<\/strong> London, UK<\/em>
\nDiscussion<\/td>\n<\/tr>\n
16:40-17:10
\n<\/strong>16:40
\n16:50
\n17:00<\/td>\n		Debate: <\/strong>That active surveillance for low risk DCIS is a reasonable option
\nYes: Shelley Potter,<\/strong> Bristol, UK<\/em>
\nNo: Henry J. Cain,<\/strong> Newcastle upon Tyne, UK<\/em>
\nDiscussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
\u00a016:10-17:10<\/strong><\/td>\n<\/a>Session 5: Metastatic HR+ve breast cancer
\n<\/span><\/strong><\/span><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nRichard de Boer, <\/strong>Melbourne, Australia
\n<\/em>Olga Oikonomidou, <\/strong>Edinburgh, Scotland, UK
\n<\/em><\/td>\n<\/tr>\n
16:10-16:40<\/strong><\/td>\nWhat to do after progression on CDKi
\nKevin Kalinsky,<\/strong> Atlanta, GA, USA<\/em><\/td>\n<\/tr>\n
16:40-17:10
\n16:40
\n16:50
\n17:00<\/strong><\/td>\n		Debate: <\/strong>That CDKi should be first line treatment for ~all HR+ve MBC\u00a0
\n<\/strong>Yes: Javier Cortes,<\/strong>\u00a0Madrid,<\/em> Spain <\/em>
\nNo: Mark Verrill,<\/strong> Newcastle upon Tyne, UK <\/em>
\nDiscussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
17:15-18:15<\/em><\/span><\/strong><\/td>\nNetworking Reception<\/em><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Thursday, September 12, 2024<\/strong><\/span><\/p>\n\n\n\n\n
\u00a007:30-08:30<\/strong><\/td>\nIndustry Breakfast Symposium<\/span><\/strong><\/a>
\nClick HERE<\/strong><\/a> for more information<\/em>
\n<\/span><\/td>\n		Hall A<\/strong><\/span><\/td>\n<\/tr>\n
<\/td>\nLight refreshments will be served, from 07:00-07:30, to session participants only.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
07:30-08:30<\/strong><\/td>\nIndustry Breakfast Symposium<\/span><\/strong><\/span><\/a>
\nClick HERE<\/strong><\/a> for more information<\/em><\/span><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
<\/td>\nLight refreshments will be served, from 07:00-07:30, to session participants only.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
\u00a008:30-09:30<\/strong><\/td>\n<\/a>Session 6: Breast cancer in young women<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nRamsey Cutress, <\/strong>Southampton, UK<\/em>
\nYazan Masannat,<\/strong>\u00a0Essex, UK<\/em><\/td>\n<\/tr>\n
08:30-09:00<\/strong><\/td>\nControversies in breast cancer management in young women
\nAnn Partridge,<\/strong> Boston, MA, USA<\/em><\/td>\n<\/tr>\n
09:00-09:30<\/strong>
\n09:00
\n09:10
\n09:20<\/td>\n		Debate:<\/strong> That women <35 with breast cancer should be advised to have bilateral total mastectomy
\nYes: Michael Alvarado,<\/strong> San Francisco, CA, USA<\/em>
\nNo: J. Michael Dixon,<\/strong> Edinburgh, Scotland, UK<\/em>
\nDiscussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n
09:30-11:00<\/strong><\/td>\n<\/a>Session 7: Screening<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nSarah Downey,<\/strong>\u00a0Norfolk, UK
\n<\/em>Laszlo Romics, <\/strong>Glasgow, Scotland, UK
\n<\/em><\/td>\n<\/tr>\n
09:30-10:00
\n<\/strong>09:30
\n09:40
\n09:50<\/td>\n		Debate: <\/strong>That a change to risk-adjusted screening is urgent and feasible
\nYes: D. Gareth Evans,<\/strong> Manchester, UK<\/em>
\nNo: Cliona Kirwan,<\/strong>\u00a0Manchester, UK<\/em>
\nDiscussion<\/td>\n<\/tr>\n
10:00-10:25<\/strong><\/td>\nCBI in screening
\nAllison Rose,<\/strong> Melbourne, Australia<\/em><\/td>\n<\/tr>\n
10:25-11:00
\n<\/strong>10:25
\n10:35
\n10:45<\/td>\n		Debate: <\/strong>That women at low risk for breast cancer should only be screened every 5 years
\nYes: Nisha Sharma,<\/strong> Leeds, UK<\/em>
\nNo: Karla Sepulveda,<\/strong>\u00a0Houston, TX, USA<\/em>
\nDiscussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n
09:30-11:00<\/strong><\/td>\n<\/a>Session 8: Triple negative breast cancer<\/span><\/strong><\/span><\/td>\nHall B<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nRichard de Boer, <\/strong>Melbourne, Australia
\n<\/em>Richard Simcock, <\/strong>Surrey, UK
\n<\/em><\/td>\n<\/tr>\n
09:30-10:10
\n<\/strong>09:30
\n09:45
\n10:00<\/td>\n		Debate: <\/strong>That\u00a0all stage 2\/3 TNBC patients should be treated according to Keynote522 regimen
\nYes: Olga Oikonomidou,<\/strong> Edinburgh, Scotland, UK<\/em>
\nNo: Carlo Palmieri,<\/strong>\u00a0Liverpool, UK<\/em>
\nDiscussion<\/td>\n<\/tr>\n
10:10-10:25<\/strong><\/td>\nTNBC subtypes: Do they have clinical significance?
\nMatthew J. Ellis,<\/strong> Houston, TX, USA<\/em><\/td>\n<\/tr>\n
10:25-11:00
\n<\/strong>10:25
\n10:35
\n10:45<\/td>\n		Debate: <\/strong>Asymptomatic patients with high-risk TNBC should undergo surveillance imaging
\nYes: Ann Partridge,<\/strong> Boston, MA, USA<\/em>
\nNo: Alistair Ring, <\/strong>London, UK<\/em>
\nDiscussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
11:00-11:30<\/em><\/span><\/strong><\/td>\nCoffee break, poster viewing and exhibition visit<\/em><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
11:30-12:30<\/strong><\/td>\n<\/a>Session 9: Metastatic Breast Cancer (MBC)<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nOlga Oikonomidou,<\/strong>\u00a0Edinburgh, Scotland, UK<\/em>
\nIain MacPherson,<\/strong>\u00a0Glasgow, Scotland, UK<\/em><\/td>\n<\/tr>\n
11:30-12:00
\n<\/strong>11:30
\n11:40
\n11:50<\/td>\n		Debate: <\/strong>That molecular testing of tumours should be routine for patients with Metastatic Breast Cancer\u00a0
\n<\/strong>Yes: Marina Parton,<\/strong> London, UK <\/em>
\n<\/strong>No: Richard de Boer,<\/strong> Melbourne, Australia<\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n
12:00-12:30
\n<\/strong>12:00
\n12:10
\n12:20<\/td>\n		Debate: <\/strong>SABR should be considered in most patients with oligometastatic breast cancer\u00a0\u00a0\u00a0\u00a0 <\/strong>
\n<\/strong>Yes: John Conibear,<\/strong> London, UK<\/em>
\n<\/strong>No: Stephen Harrow,<\/em><\/strong> Edinburgh, Scotland, UK <\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n
11:30-12:30<\/strong><\/td>\n<\/a>Session 10:
\nFree Papers: Surgical<\/span><\/strong><\/span><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nLynda Wyld,<\/strong>\u00a0Sheffield, UK<\/em>
\nRaghavan Vidya,<\/strong>\u00a0Birmingham, UK<\/em><\/td>\n<\/tr>\n
11:30-11:40<\/strong><\/td>\nVariation in practice and provision of contralateral symmetrising mastectomy after unilateral mastectomy for breast cancer: A UK national practice survey
\nKatherine Fairhurst,<\/strong> Bristol, UK<\/em><\/td>\n<\/tr>\n
11:40-11:50<\/strong><\/td>\nMammographic surveillance in early breast cancer patients aged 50 years or over: Results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
\nJanet Dunn,<\/strong> Coventry, UK<\/em><\/td>\n<\/tr>\n
11:50-12:00<\/strong>
\n<\/strong><\/td>\n		Oncoplastic breast conservation surgery increases survival in comparison to mastectomy in a west of Scotland population-based study with long-term follow-up
\nMhairi Mactier,<\/strong> Glasgow, Scotland, UK<\/em><\/td>\n<\/tr>\n
12:00-12:10<\/strong>
\n<\/strong><\/td>\n		Uptake of breast cancer screening with mammography and ultrasound in China: A multi-centre population-based study
\nYadi Zheng,<\/strong> Beijing, China<\/em><\/td>\n<\/tr>\n
12:10-12:20<\/strong><\/td>\nCumulative risk of cosmetic worsening following ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost: Largest real-world data
\nTabassum Wadasadawala,<\/strong> Mumbai, India<\/em><\/td>\n<\/tr>\n
12:20-12:30<\/strong><\/td>\nFactors influencing immediate reconstruction and complications for gene carriers in those undergoing mastectomy in KConFAb population
\nAnita Skandarajah, <\/strong>Melbourne, Australia<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
\u00a012:30-13:30<\/strong><\/td>\nPre-Lunch Industry Symposium<\/span><\/strong><\/a>
\nClick HERE<\/strong><\/a> for more information<\/em>
\n<\/span><\/strong><\/span><\/td>\n		Hall A<\/strong><\/span><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
12:30-13:30<\/strong><\/td>\nPre-Lunch Industry Symposium<\/span><\/strong><\/a>
\nClick HERE<\/strong><\/a> for more information<\/em>
\n<\/span><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
13:30-14:30<\/em><\/span><\/strong><\/td>\nLunch break, poster viewing and exhibition visit<\/em><\/strong><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n
14:30-15:30<\/strong><\/td>\n<\/a>Session 11: Genetics<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nAlastair Thompson,<\/strong> Houston, TX, USA<\/em>
\nDouglas Ferguson, <\/strong>Exeter,<\/em> UK<\/em><\/td>\n<\/tr>\n
14:30-15:00
\n<\/strong>14:30
\n14:40
\n14:50<\/td>\n		Debate: <\/strong>That most cancer patients with gene mutations should be offered breast conservation \u00a0
\n<\/strong>Yes: D. Gareth Evans,<\/strong> Manchester, UK<\/em>
\n<\/strong>No: Stuart McIntosh,<\/strong>\u00a0Belfast, UK<\/em>\u00a0
\n<\/strong>Discussion<\/td>\n<\/tr>\n
15:00-15:15\u00a0<\/strong><\/td>\nThe ‘new genes’: What do they mean for patients and families?
\nJennie Murray, <\/strong>Edinburgh, Scotland, UK<\/em> \u00a0<\/em><\/td>\n<\/tr>\n
15:15-15:30\u00a0<\/strong><\/td>\nWhat is the appropriate timing of risk reduction BSO in BRCA patients?
\nSukhwinder Sahota,<\/strong> Edinburgh, Scotland, UK <\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n
14:30-15:30<\/strong><\/td>\n<\/a>Session 12:
\nFree Papers: Medical oncology<\/span><\/strong><\/span><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nRichard de Boer,<\/strong> Melbourne, Australia
\n<\/em>Carlo Palmieri,<\/strong>\u00a0Liverpool, UK
\n<\/em><\/td>\n<\/tr>\n
14:30-14:40<\/strong><\/td>\nIdentifying oestrogen receptor-related genes of predictive value in breast cancer
\nShorouk Makhlouf,<\/strong> Nottingham, UK<\/em><\/td>\n<\/tr>\n
14:40-14:50<\/strong><\/td>\nPathological complete response rate in neoadjuvant chemotherapy versus concurrent chemo-endocrine therapy in hormone receptor positive, HER2 negative breast cancer
\nShalaka Joshi,<\/strong> Mumbai, India<\/em><\/td>\n<\/tr>\n
14:50-15:00<\/strong>
\n<\/strong><\/td>\n		Why have health technology assessment boards reached differing conclusions about the ability of tumour gene expression tests to predict chemotherapy benefit for postmenopausal breast cancer patients?
\nRobert Stein,<\/em><\/strong> London, UK<\/em><\/td>\n<\/tr>\n
15:00-15:10<\/strong>
\n<\/strong><\/td>\n		A morphometric signature for HER2 activity predicts recurrence risk in breast cancer
\nNehal Atallah,<\/strong> Nottingham, UK<\/em><\/td>\n<\/tr>\n
15:10-15:20<\/strong><\/td>\nSomething old, new or borrowed: Optimum second line therapy after CDK4-6 inhibition
\nAndrew Redfern,<\/strong> Murdoch, Australia<\/em><\/td>\n<\/tr>\n
15:20-15:30<\/strong><\/td>\nDiscussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
15:30-16:00<\/em><\/span><\/strong><\/td>\nCoffee break, poster viewing and exhibition visit<\/em><\/strong><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n
16:00-17:30<\/strong><\/td>\n<\/a>Session 13: Adjuvant endocrine therapy<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nCliona Kirwan, <\/strong>Manchester, UK <\/em>
\nJohn Benson,<\/strong> Cambridge, UK<\/em><\/td>\n<\/tr>\n
16:00-16:45<\/strong><\/td>\nWhy my assay is best<\/td>\n<\/tr>\n
16:00<\/td>\nPAM 50
\nMatthew J. Ellis, <\/strong>Houston, TX, USA<\/em><\/td>\n<\/tr>\n
16:15<\/td>\nThe Oncotype DX Breast Recurrence Score\u00ae test
\nKevin Kalinsky, <\/strong>Atlanta, GA, USA <\/em><\/td>\n<\/tr>\n
16:30
\n<\/strong><\/td>\n		Mammaprint
\nWilliam Audeh,<\/strong> Los Angeles, CA, USA<\/em><\/td>\n<\/tr>\n
16:45-17:30
\n<\/strong>16:45
\n17:00
\n17:15<\/td>\n		Debate: <\/strong>That adjuvant CDKs should be recommended for intermediate risk ER+HER2-EBC
\n<\/strong>Yes: Kevin Kalinsky, <\/strong>Atlanta, GA, USA<\/em>
\n<\/strong>No: Alistair Ring,<\/strong> London, UK<\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Friday, September 13, 2024<\/strong><\/span><\/p>\n\n\n\n\n
\u00a007:30-08:30<\/strong><\/td>\nIndustry Breakfast Symposium<\/span><\/strong><\/a>
\nClick HERE<\/strong><\/a> for more information<\/em>
\n<\/span><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
<\/td>\nLight refreshments will be served, from 07:00-07:30, to session participants only.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
08:30-10:00<\/strong><\/td>\n<\/a>Session 14: Reconstruction<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nLeena Chagla,<\/strong> Cheshire, UK
\n<\/em>Krishna Clough, <\/strong>Paris, France
\n<\/em><\/td>\n<\/tr>\n
08:30-09:00<\/strong><\/td>\nFat grafting, realistic expectations and long-term results
\nKrishna Clough, <\/strong>Paris, France <\/em><\/td>\n<\/tr>\n
09:00-10:00<\/strong><\/td>\nMDT Round Table Discussion on tricky oncoplastic\/reconstructive topics
\n
\nCase presenters:
\n<\/strong><\/strong>Rajiv Dave, <\/strong>Manchester, UK<\/em>\u00a0<\/em>
\n<\/strong><\/strong>Kenneth Elder, <\/strong>Edinburgh, Scotland, UK<\/em><\/em><\/em>Panel:
\n<\/strong>J. Michael Dixon,<\/strong>\u00a0<\/span>Edinburgh, Scotland, UK
\n<\/em>Adam Gilmour,<\/strong> Glasgow, Scotland, UK
\n<\/em><\/em>Andrew Malyon,<\/strong> Glasgow, Scotland, UK <\/em>
\n<\/em>James Mansell,<\/strong> Glasgow, Scotland, UK
\n<\/em><\/em>Lynda Wyld,<\/strong>\u00a0Sheffield, UK
\n<\/em><\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n
08:30-10:00<\/strong><\/td>\n<\/a>Session 15: Managing side effects of hormone treatment in breast cancer?
\nAn interactive session<\/span><\/strong><\/span><\/td>\n		Hall B<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nOlga Oikonomidou, <\/strong>Edinburgh, Scotland, UK
\n<\/em>Katy Ellis, <\/strong>Manchester, UK<\/em><\/td>\n<\/tr>\n
08:30-09:20<\/strong><\/td>\nManaging oestrogen deprivation effects of therapy: Real world patient
\nLesley Fallowfield,<\/strong> Sussex, UK<\/em><\/td>\n<\/tr>\n
09:20-09:30<\/strong><\/td>\nPrescribing exercise or dietary modifications in breast cancer: A real trend or just a fad?
\nMarina Parton,<\/strong> London, UK<\/em><\/td>\n<\/tr>\n
09:30-09:50<\/strong><\/td>\nSymptoms of menopause and how to manage them following breast cancer
\nPaula Briggs,<\/strong> Liverpool, UK<\/em><\/td>\n<\/tr>\n
09:50-10:00<\/strong><\/td>\nQ&A<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
10:00-10:30<\/em><\/span><\/strong><\/td>\nCoffee break, poster viewing and exhibition visit<\/em><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
10:30-11:30<\/strong><\/td>\n<\/a>Session 16: Locoregional management<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nKrishna Clough, <\/strong>Paris, France <\/em>
\nStephen Grobmyer, <\/strong>Abu Dhabi, UAE<\/em><\/td>\n<\/tr>\n
10:30-11:00
\n<\/strong>10:30
\n10:40
\n10:50<\/td>\n		Debate: <\/strong>That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
\n<\/strong>Yes: Alastair Thompson,<\/strong> Houston, TX, USA<\/em>
\n<\/strong>No: Leena Chagla,<\/strong> Cheshire, UK<\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n
11:00-11:30
\n<\/strong>11:00
\n11:10
\n11:20<\/td>\n		Debate: <\/strong>That all patients with 1-3 macrometastases in axillary nodes should have Regional Nodal Radiation\u00a0\u00a0
\n<\/strong>Yes: Elinor Sawyer,<\/strong> London, UK<\/em>\u00a0
\n<\/strong>No: Michael Douek, <\/strong>London, UK <\/em>
\n<\/strong>Discussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n
11:30-12:30<\/strong><\/td>\n<\/a>Session 17: Breast cancer 2035<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nLeena Chagla, <\/strong>Cheshire, UK<\/em>
\nBruce Mann,<\/strong> Melbourne,<\/em> Australia<\/em><\/td>\n<\/tr>\n
11:30-11:45<\/strong><\/td>\nOncoplastic surgery in 2035
\nKrishna Clough, <\/strong>Paris, France <\/em><\/td>\n<\/tr>\n
11:45-12:00<\/strong><\/td>\nEarly detection in 2035
\nKarla Sepulveda,<\/strong>\u00a0Houston, TX, USA<\/em><\/td>\n<\/tr>\n
12:00-12:15<\/strong><\/td>\nManagement of stage 1 breast cancer in 2035
\nBruce Mann,<\/strong> Melbourne, Australia<\/em><\/td>\n<\/tr>\n
12:15-12:30<\/strong><\/td>\nSystemic therapy in 2035
\nOlga Oikonomidou, <\/strong>Edinburgh, Scotland, UK<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
\u00a012:30-12:45<\/strong><\/td>\n<\/a>Congress closing and Award presentation<\/span><\/strong><\/span><\/td>\nHall A<\/strong><\/span><\/td>\n<\/tr>\n
Chairpersons<\/strong><\/td>\nLeena Chagla<\/strong>, Cheshire, UK
\n<\/em>Bruce Mann, <\/strong>Melbourne, Australia
\n<\/em><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
    \n
  • Program is subject to change<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    Scientific Program Click on the picture below to view the full scientific program and abstracts (pdf version which can be printed)\u00a0 Wednesday, September 11, 2024 12:00-13:00 [\u2026]<\/span><\/p>\n","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4584","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/4584"}],"collection":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/comments?post=4584"}],"version-history":[{"count":701,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/4584\/revisions"}],"predecessor-version":[{"id":10234,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/4584\/revisions\/10234"}],"wp:attachment":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/media?parent=4584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}